General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel and Fax: +30-22950-53389; e-mail: journals@iiar-anticancer.org

For more information about IN VIVO, IIAR and the conferences please visit the IIAR websites: www.iiar-anticancer.org and www.iv.iiarjournals.org

Selection of Recent Articles

Effect of Radiation and Repeated Sub-culturing on the Transforming Growth Factor-β1 Signaling Pathway in FRTL-5 Cells. C.G. BURRELL, D.S. GRIDLEY, L.S. ORTLOFF, S.M. CHARLES, L.M. GREEN (Loma Linda, CA; Winston-Salem, NC, USA)

IL6 Plasma Concentrations in Patients with Sepsis Receiving SLED and Antibiotics: A Predictor for Survival. T.R. MCGUIRE, N.T. REARDON, K. BOGARD, T.J. PLUMB, C.J. BULTSMA, S.W. NISSEN, P.D. FULLER, K.M. OLSEN (Omaha, NE; Ocala, FL, USA)


Effect of GPIIb/IIIa Inhibition with Eptifibatide or Tirofiban on the Expression of Cellular Adhesion Molecules on Monocytes. S. SWOBODA, T. WALTER, S. LANG, H.-P. WENDEL, M.E. BEYER, E. GRIESEL, H.-M. HOFFMEISTER, J. GRUETTNER (Heidelberg; Tuebingen; Kirchheim; Solingen, Germany)

Tolerated Doses in Zebrafish of Cytochalasins and Jasplakinolide for Comparison with Tolerated Doses in Mice in the Evaluation of Pre-clinical Activity of Microfilamentdirected Agents in Tumor Model Systems In Vivo. M. TRENDOWSKI, V. WONG, K. WELLINGTON, S. HATFIELD, T.P. FONDY (Syracuse, NY, USA)

A Novel Role of CYP2E1 in Human Megakaryocyte Development. Y. TANG, G. ZHANG, M. BAIRD, F. RACKE, W. ZHAO (Columbus, OH; San Juan Capistrano, CA, USA)


Sex Hormones Differentially Modulate STAT3-dependent Antioxidant Responses during Oxidative Stress in Renal Proximal Tubule Cells. D.K. REED, I. ARANY (Jackson, MS, USA)

Effect of Melatonin on Human Nighttime Endotoxaemia: Randomized, Double-blinded, Cross-over Study. M. ALAMIL, K. BENDTZEN, J. LYKKEFELDT, J. ROSENBERG, I. GÖGENUR (Køge; Copenhagen; Herlev, Denmark)

The Success Rate in a Complicated Spatial Memory Test Is Determined by Age, Sex, Life History and Search Strategies in Cynomolgus Monkeys. H.S. DARUSMAN, O. KALLIKOIKSI, D. SAJUTHI, A. SCHAPIRO, A. GJEDDE, J. HAU (Copenhagen; Aarhus, Denmark; Bogor, Indonesia; Bastrop, TX; Baltimore, MD, USA; Montréal, QC, Canada)

No Changes in Cerebral Microcirculatory Parameters in Rat During Local Cortex Exposure to Microwaves. H. MASUDA, S. HIROTA, A. USHIYAMA, A. HIRATA, T. ARIMA, H. WATANABE, K. WAKE, S. WATANABE, M. TAKI, A. NAGAI, C. OHKUBO (Tokyo; Saitama; Aichi, Japan)

Improving the Bioavailability and Anticancer Effect of the PCA-1/ALKBH3 Inhibitor HUHS015 Using Sodium Salt. M. MABUCHI, T. SHIMIZU, M. UEDA, Y. SASAKAWA, S. NAKAO, Y. UEDA, A. KAWAMURA, K. TSUIJIKAWA, A. TANAKA (Kobe; Osaka; Saitama; Kansai, Japan)


Instructions to Authors 2015

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTI Cancer RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTI CANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2015 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
A Selection of Recent Articles

The Metastasis Suppressor NME1 Regulates Expression of Genes Linked to Metastasis and Patient Outcome in Melanoma and Breast Carcinoma. J.R. MCCORKLE, M.K. LEONARD, S.D. KRANER, E.M. BLALOCK, D. MA, S.G. ZIMMER, D.M. KAETZEL (Memphis, TN; Baltimore, MD; Lexington, KY; Iowa City, IA, USA)

Profiling of Chromosomal Changes in Potentially Malignant and Malignant Oral Mucosal Lesions from South and South-East Asia Using Array-Comparative Genomic Hybridization. M.L.S. LUNDE, E. ROMAN, S. WARNAKULASURIYA, R. MEHROTRA, J. LARANNE, E.N. VASSTRAND, S.O. IBRAHIM (Bergen, Norway; London, UK; Allahabad, India; Tampere, Finland)

Expression of Claudins in Human Clear Cell Renal Cell Carcinoma. W. MEN, T.A MARTIN, F. RUGE, N. ZHANG, P. DU, Y. YANG, W.G. JIANG (Beijing, China; Cardiff, UK)


Phenome-Genome Association Studies of Pancreatic Cancer: New Targets for Therapy and Diagnosis. R. NARAYANAN (Boca Raton, FL, USA)


Quantitative Proteomics of Bronchoalveolar Lavage Fluid in Lung Adenocarcinoma. S.A. ALMATROODI, C.F. MCDONALD, A.L. COLLINS, I.A. DARBY, D.S. POUNIOTIS (Bundoora; Heidelberg, VIC, Australia; Buraidah, Saudi Arabia)

Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma. A. BOTEZATU, C. BLEOTU, A. NASTASE, G. ANTON, N. BACALBASA, D. DUDA, S.O. DIMA, I. POPESCU (Bucharest, Romania; Charlestown, MA, USA)
Subscription Order Form 2015

☐ Please enter a Subscription to ANTIканцер RESEARCH Volume 35 (2015).

Annual subscription rates (2015): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online; Prices include rapid delivery and insurance.

2015 online subscriptions include free online access to vol. 24 (2004) - 34 (2014).

☐ Please send me the following previous volumes (1-34) at 50% discount on the above rates.

☐ Payment is enclosed. ☐ Please invoice.

Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)

☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ................................................................................................................................................................
..................................................................................................................................................................................................
Tel: ..........................................................................................................................................................................................
Fax: .........................................................................................................................................................................................
Signature: .............................................................................................................................................................................
Date: ...................................................................................................................................................................................

Please send this order to ANTIканцер RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2015 Offers to Authors of ANTIканцер RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2015 on a basis of priority and availability. Effective from January to December 2015).

- Included in Pubmed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTIканцер RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2015

☐ I am one of the authors of the article published in Anticancer Research Vol. ......., pp. .........., year .........

☐ Please enter my personal subscription to Anticancer Research 2015 (Volume 35) at the special Author’s rate of Euro 390.00 (print or online).

☐ Please send me previous Volume No(s) .............. at Euro 195.00 (print) per volume.

☐ Please enter my personal combined 2015 subscription to Anticancer Research (Volume 35) and IN VIVO (Volume 29) at Euro 560.00 (print or online).

☐ My payment is enclosed.

☐ Please send me an invoice.

Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: ................................................................................................................................................................
..................................................................................................................................................................................................
Tel-Fax: .......................................................................................................................................................................................
e-mail: .......................................................................................................................................................................................
Date and signature: ...............................................................................................................................................................
Treatment Outcome of Radiotherapy for Localized Primary Ocular Adnexal MALT Lymphoma – Prognostic Effect of the AJCC Tumor- Node-Metastasis Clinical Staging System. S. OHGA, K. NAKAMURA, Y. SHIOYAMA, T. SASAKI, T. YAMAGUCHI, T. YOSHITAKE, K. TERASHIMA, K. ASAI, K. MATSUMOTO, H. HONDA (Fukuoka; Saga, Japan) ................................................................. 3591

ABSTRACTS OF THE INTERNATIONAL SYMPOSIUM “BIOLOGIC EFFECTS OF LIGHT” 11-12 June, 2015 Schlossberg Hotel, Homburg/Saar, Germany ................................................................................................................................. 3599

ABSTRACTS OF THE 25th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO) 21-23 June, 2015, Rome, Italy ......................................................................................................................... 3615

Errata ............................................................................................................................................ 3741
Preoperative Prediction of Peritoneal Metastasis in Gastric Cancer as an Indicator for Neoadjuvant Treatment. M. OHI, K. MORI, Y. TOIYAMA, Y. MOHRI, M. OKIGAMI, H. YASUDA, S. SAIGUSA, K. TANAKA, Y. INOUE, M. KUSUNOKI (Mie, Japan) ................................................................. 3511

The Role of Quaternary Cytoreduction in Recurrent Epithelial Ovarian Cancer: A Single-center Experience. N. BACALBAȘA, I. BALESCU, S. DIMA, V. BRASOVEANU, I. POPESCU (Bucharest, Romania) .......................... 3519


Evaluation of IL-2, IL-6, IL-8 and IL-10 in Malignant Melanoma Diagnostics. R. KUCERA, O. TOPOLCAN, I. TRESKOVA, J. KINKOROVA, J. WINDRICHova, R. FUCHSOVA, S. SVOBODOVA, V. TRESKA, V. BABUSKA, J. NOVAK, J. SMEJKAL (Prague, Czech Republic) ....................................................................................................................... 3537

Hopelessness/Helplessness in Healthy Individuals and in Patients with Benign Breast Disease and Breast Cancer: A Prospective Case–control Study in Finland. M. ESKELINEN, R. KORHONEN, T. SELANDER, P. OLLONEN (Kuopio, Finland) .............................................................................. 3543

The Impact of Perioperative Allogeneic Blood Transfusion on Survival in Elderly Patients with Colorectal Cancer. M. KANEKO, S. SASAKI, K. ISHIMARU, E. TERAI, H. NAKAYAMA, T. WATANABE (Tokyo, Japan) .......................................................................................................................... 3553

Cerebral Relapsing Meningioma: A Surgical Series with Lack of Reliability of Standard Parameters Establishing Prognosis. F. FOREST, V. YVOREL, F. VASSAL, B. TROMBERT, J.-M. DUMOLLARD, C. NUTI, M. PÉOC’H (Saint Étienne, France) ................................................................. 3559

Short-term Survival of Patients with Lung Metastases from Colorectal and Non-colorectal Cancer Who Underwent Pulmonary Metastasectomy. F. LUMACHI, F. MAZZA, A. DEL CONTE, G. LO RE, M. ERMANI, G.B. CHIARA, S.M.M. BASSO (Padova; Pordenone, Italy) ........................................................................................................... 3563

PSA Isoforms’ Velocities for Early Diagnosis of Prostate Cancer. I. HEIDEGGER, H. KLOCKER, R. PICHLER, W. HORBINGER, J. BEKTING (Innsbruck, Austria) ........................................................................................................ 3567

Impact of Stereotactic Radiosurgery Dose on Control of Cerebral Metastases from Renal Cell Carcinoma. D. RADES, S. HUTTENLOCHER, N. GEBAUER, D. HORNUNG, N.T. TRANG, M.T. KHOA, S.E. SCHILD (Lübeck; Hamburg, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA) .................................................................................................................. 3571

Frequent High Expression of Kita-Kyushu Lung Cancer Antigen-1 (KK-LC-1) in Gastric Cancer. A. SHIDA, N. FUTAWATARI, T. FUKUYAMA, Y. ICHIKI, Y. TAKAHASHI, Y. NISHI, N. KOYABASHI, H. YAMAZAKI, M. WATANABE (Kitamoto, Saitama; Kitakyushu, Fukuoka; Sagamihara, Kanagawa, Japan) .......................................................................................................................... 3575

Significance of Lymphatic Invasion Combined with Size of Primary Tumor for Predicting Sentinel Lymph Node Metastasis in Patients with Breast Cancer. T. FUJI, R. YAJIMA, H. TATSUKI, T. SUTO, H. MORITA, S. TSUTSUMI, H. KUWANO (Maebashi, Gunma, Japan) .......................................................................................................................... 3581

New Approach to Complete Video-assisted Thoracoscopic Lobectomy in T2 and T3 Non-Small Cell Lung Cancer. M. KATO, H. ONISHI, K. FURUGAKI, S. YUNOTANI, K. MATSUMOTO, N. TSURUTA, K. NAKAMURA, M. KATANO (Karatsu, Saga; Fukuoka, Japan) .......................................................................................................................... 3585

Contents continued on the preceding page
AGO Score As a Predictor of Surgical Outcome at Secondary Cytoreduction in Patients with Ovarian Cancer. M.Z. MUALLEM, K. GASIMLI, R. RICHTER, J. ALMUHEIMID, S. NASSER, E.I. BRAICU, J. SEHOULI (Berlin, Germany) ................................................................. 3423

A Cohort Study Evaluating the Role of Surgery for Lung Metastases from Colorectal Cancer. F. SOCOLA, D.M. NGUYEN, R.E. OCHOA, C.M. ROCHA LIMA, P.J. HOSEIN (Little Rock, AR; Miami, FL; Lexington, KY, USA) .................................................. 3431

Second Primary Malignancies in Mantle Cell Lymphoma: A U.S. Population-based Study. B.K. SHAH, A. KHANAL (Lewiston, ID; Chicago, IL, USA) .......................................................... 3437

Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (≥75 years) Patients. G.-C. MATTIUCCI, M. FALCONI, R.G.P.M. VAN STIPHOUT, S. ALFIERI, F.A. CALVO, J.M. HERMAN, B.W. MAIDMENT III, R.C. MILLER, W.F. REGINE, M. RENI, N. SHARMA, S. PARTELLI, D. GENOVESE, M. BALDUCCI, F. DEODATO, V. VALENTINI, A.G. MORGANTI (Rome; Verona; Milan; Ancona; Chieti; Campobasso, Italy; Maastricht, the Netherlands; Madrid, Spain; Baltimore, MD; Charlottesville, VA; Rochester, MN, USA) .............................................................. 3441


Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry. I. KOCAKOVA, B. MELICHAR, I. KOCAK, Z. BORTLICEK, T. BUCHLER, L. DUSEK, L. PETRUZELKA, M. KOHOUTEK, J. PRAUSOVÁ, J. FINEK, B. MOHELNIKOVA-DUCHONOVA, R. VYZULA (Brno; Olomouc; Prague; Zlin; Plzen, Czech Republic) .............. 3455

Preoperative Leucocytosis, Thrombocytosis and Anemia as Potential Prognostic Factors in Non-metastatic Renal Cell Carcinoma. G.C. HUTTERER, D. KRIEGER, E. MRSIC, K. POHLMANN, A. BEZAN, T. STOJAKOVIC, K. PUMMER, R. ZIGEUNER, M. PICHLER (Graz, Austria; Houston, TX, USA) ............ 3463

Non-menopausal Status, High Nuclear Grade, Tumor Size >30 mm and Positive Resection Margins Are Predictors of Residual Tumor After Lumpectomy for Ductal Carcinoma In Situ of the Breast. M. JOSTE, V. MENDES, S. TIXIER, C. PALPACUER, B. LAVIOLLE, J. LEVEQUE, L. OULDAMER (Rennes; Tours; Angers, France) .......................................................... 3471

Role of Pelvic and Para-aortic Lymph Node Metastases in Optimally Cytoreduced Advanced Ovarian Cancer. C. BACHMANN, R. BACHMANN, S.Y. BRUCKER, A. STAEBLER, F. FEND, D. WALLWIENER, E.-M. GRISCHKE (Tübingen, Germany) .............................................. 3479

Sentinel Node Navigation Surgery for Lower Rectal Cancer. H. KAWAHARA, K. WATANABE, H. ENOMOTO, M. TOMODA, T. AKIBA, K. YANAGA (Chiba; Tokyo, Japan) .................................................. 3485

Telomere Length Abnormalities and Telomerase RNA Component Expression in Gastroenteropancreatic Neuroendocrine Tumors. H.S. KIM, H.S. LEE, K.H. NAM, J. CHOI, W.H. KIM (Seoul; Gyeonggi-do; Busan, Republic of Korea) .......................... 3501

Contents continued on the preceding page
Correlation of HIWI and HILI Expression with Cancer Stem Cell Markers in Colorectal Cancer. M. LITWIN, J. DUBIS, K. ARCZYŃSKA, A. PIOTROWSKA, A. FRYDLEWICZ, M. KARCZEWSKI, P. DZIEGIEL, W. WITKIEWICZ (Wroclaw, Poland) ................................................................. 3317

Differential Genomic Damage in Different Tumor Lines Induced by Prodigiosin. J.C. LAPENDA LINS, M.E.B. DE MELO, S.C. DO NASCIMENTO, M.L. ADAM (Recife; Pernambuco, Brazil) .................. 3325


Characterization of Cells Cultured from Chylous Effusion from a Patient with Sporadic Lymphangioleiomyomatosis. I. GRZEGOREK, E. ZUBA-SURMA, M. CHABOWSKI, D. JANCZAK, A. SZUBA, P. DZIEGIEL (Wroclaw; Krakow, Poland) .................................................. 3341

Immunohistochemical Evaluation of Pulmonary Lymphangioleiomyomatosis. I. GRZEGOREK, D. LENZE, M. CHABOWSKI, D. JANCZAK, M. SZOLKOWSKA, R. LANGFORT, A. SZUBA, P. DZIEGIEL (Wroclaw, Poland; Berlin, Germany) ........................................................................................................................................... 3353

Characterization of α-, β- and p120-Catenin Expression in Feline Mammary Tissues and their Relation with E- and P-Cadherin. A.C. FIGUEIRA, C. GOMES, H. VILHENA, S. MIRANDA, J. CARVALHEIRA, A.J.F. DE MATOS, P. DIAS-PEREIRA, F. GÄRTNER (Coimbra; Porto; Águeda; Vila Real; Vairão, Portugal) ......... 3361

Biochemical Action of New Complexes of Ruthenium with Quinolones as Potential Antitumor Agents. M.I. GRUIA, V. NEGOITA, M. VASILESCU, M. PANAIT, I. GRUIA, B.S. VELESCU, V. UIVAROSI (Bucharest, Romania) ............................................................. 3371


Clinical Studies

Effective Treatment of Transmissible Venereal Tumors in Dogs with Vincristine and IL2. W. DEN OTTER, M. HACK, J.J.L. JACOBS, J.F.V. TAN, L. ROZENDAAL, R.J.A. VAN MOORSELAAR (Amsterdam; Gouda, the Netherlands; Rondeklip, Curacao) .............................................. 3385

Cyclin E Expression Correlates with Cancer-specific Survival in Endometrial Endometrioid Adenocarcinoma. S. SANTALA, A. TALVENAARI-MATTILA, Y. SOINI, M. SANTALA (Oulu; Kuopio, Finland) ........ 3393

Effective Therapeutic Intervention and Comprehensive Genetic Analysis of mTOR Signaling in PEComa: A Case Report. F. WEEBER, M.J. KOUDJIS, M. HOOGSTRAAT, N.J.M. BESSELINK, S. VAN LIJSHOUT, I.J. NIJMAN, E. CUPPEN, G.J. OFFERHAUS, E.E. VOEST (Amsterdam; Utrecht, the Netherlands) ............ 3399

Atypical Paracaval Recurrence of Uterine Endometrial Stromal Sarcoma: A Case Report. N. BACALBAȘA, I. BALESCU (Bucharest, Romania) ......................................................................................................................... 3405


Duration of First-line Treatment with Molecular Targeted-Therapy Is a Prognostic Factor in Metastatic Renal Cell Carcinoma. K. UEDA, S. SUEKANE, K. NISHIHARA, N. OGASAWARA, H. KUROSE, S. HAYASHI, K. CHIKUI, S. SUYAMA, M. NAKIRI, M. MATSUO, T. IGAWA (Fukuoka, Japan) .............. 3415

Contents continued on the preceding page
Reduced Expression of RECK Protein May Help Differentiate Cutaneous Malignant Melanoma from Melanocytic Nevus. L. ZHANG, Q. XIE, S.-J. SHAN, M.K. TABOR, J.M. JUNKINS-HOPKINS (Nanchang; Tianjin, PR China; New York, NY, USA) ................................................................................................................................. 3185

Combination Efficacy of *Astragalus membranaceus* and *Curcuma wenyujin* at Different Stages of Tumor Progression in an Imageable Orthotopic Nude Mouse Model of Metastatic Human Ovarian Cancer Expressing Red Fluorescent Protein. G. YIN, D. TANG, J. DAI, M. LIU, M. WU, Y. SUN, Z. YANG, R.M. HOFFMAN, L. LI, S. ZHANG, X. GUO (Nanjing, Jiangsu, PR China; San Diego, CA, USA) ................................................................................................................................. 3193

MicroRNA-145 Promotes the Phenotype of Human Glioblastoma Cells Selected for Invasion. S. KOO, G. MARTIN, L.G. TOUSSAINT (Bryan, TX, USA) ................................................................................................................................. 3209

Inflammation-Related Tumor Progression in Murine Fibrosarcoma Exhibited Over-expression of Sex-determining Region Y-box 2 (Sox2) Compared to Parental Regressor Cells. Y. KURAMITSU, I. TANAKA, Y. WANG, F. OKADA, K. TOKUDA, T. KITAGAWA, J. AKADA, K. NAKAMURA (Ube; Shunan, Yamaguchi; Yonago, Japan) ................................................................................................................................................................. 3217

Gene Expression Profiling of MCF10A Breast Epithelial Cells Exposed to IOERT. L. MINAFRA, V. BRAVATÀ, G. RUSSO, G.I. FORTE, F.P. CAMMARATA, M. RIPAMONTI, G. CANDIANO, M. CERVELLO, A. GIALLONGO, G. PERCONTI, C. MESSA, M.C. GILARDI (Cefalù; Palermo; Milan; Monza, Italy) ................................................................................................................................................................. 3223

Induction of G1 Arrest by SB266510 Involves Cyclin D3 Downregulation and Suppression of CDK2 (Thr160) Phosphorylation. A.E. GODA, R.L. ERIKSON, J.-S. AHN, B.-Y. KIM (Cheongwon, Republic of Korea; Cambridge, MA, USA; Tanta, Egypt) ................................................................................................................................................................. 3235

Reversal of ABCB1-related Multidrug Resistance of Colonic Adenocarcinoma Cells by Phenothiazines. D. TAKÁCS, Á. CSONKA, Á. HORVÁTH, T. WINDT, M. GAJDÁCS, Z. HAJÓS, L. AMARAL, J. MOLNÁR, G. SPENGLER (Budapest; Szeged, Hungary; Lisbon, Portugal) ................................................................................................................................................................. 3245

Differential Gene Regulation in Fibroblasts in Co-culture with Keratinocytes and Head and Neck SCC Cells. M. HAKELIUS, D. SAIEPOUR, H. GÖRANSSON, K. RUBIN, B. GERDIN, D. NOWINSKI (Uppsala, Sweden) ................................................................................................................................................................. 3253

ROCK I Has More Accurate Prognostic Value than MET in Predicting Patient Survival in Colorectal Cancer. J. LI, S.S. BHARADWAJ, G. GUZMAN, R. VISHNUBHOTLA, S.C. GLOVER (Gainesville, FL; Chicago, IL, USA) ................................................................................................................................................................. 3267

Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model. J. MACKIEWICZ, U. KAZIMIERCZAK, M. KOTLARSKI, E. DONDAJEWSKA, A. KOZŁOWSKA, E. KWiatKOWSKA, A. NOWICKA-KOTLARSKA, H. DAMS-KOZŁOWSKA, P.J. WYSOCKI, A. MACKIEWICZ (Poznan, Poland) ................................................................................................................................................................. 3275

Microarray Analysis Reveals Distinct Gene Set Profiles for Gastric and Intestinal Gastrointestinal Stromal Tumors. R. HARA, H. KIKUCHI, T. SETOGUCHI, S. MIYAZAKI, M. YAMAMOTO, Y. HIRAMATSU, K. KAMIYA, M. OHTA, S. BABA, H. KONNO (Hamamatsu, Japan) ................................................................................................................................................................. 3289

MCP1-Induced Epithelial–Mesenchymal Transition in Head and Neck Cancer by AKT Activation. C.-C. LEE, H.-C. HO, Y.-C. SU, M.-S. LEE, S.-K. HUNG, C.-H. LIN (Chiayi; Hualien, Taiwan, ROC) ................................................................................................................................................................. 3299

Bortezomib Causes ER Stress-related Death of Acute Promyelocytic Leukemia Cells Through Excessive Accumulation of PML–RARα. M. TAKENOKUCHI, K. MIYAMOTO, K. SAIGO, T. TANIGUCHI (Hyogo, Japan) ................................................................................................................................................................. 3307

Contents continued on the preceding page